# Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

> **NCT06970951** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
- Dry Syndrome
- Idiopathic Inflammatory Myopathies
- Systemic Sclerosis

## Interventions

- **BIOLOGICAL:** UTAA91 injection

## Key facts

- **NCT ID:** NCT06970951
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-18
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06970951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06970951, "Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06970951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*